

# Press Releases

All Years

[Advanced Search](#)

MAY 26, 2026

## [Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference](#)

---

MAY 6, 2026

## [Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations](#)

---

APR 30, 2026

## [Perrigo Completes Divestiture of Dermacosmetics Business](#)

---

APR 29, 2026

## [Perrigo Announces Quarterly Dividend](#)

---

APR 22, 2026

## [Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026](#)

---

MAR 3, 2026

## [Perrigo to Present at the UBS Global Consumer and Retail Conference](#)

---

FEB 26, 2026

**[Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations](#)**

---

FEB 19, 2026

**[Perrigo Announces Quarterly Dividend](#)**

---

FEB 13, 2026

**[Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026](#)**

---

NOV 18, 2025

**[Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference](#)**

---

NOV 5, 2025

**[Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations](#)**

---

NOV 5, 2025

**[Perrigo to Conduct Strategic Review of its Infant Formula Business](#)**

---

NOV 4, 2025

**[Perrigo to Attend Jefferies Consumer Conference](#)**

---

OCT 29, 2025

**[Perrigo Announces Quarterly Dividend](#)**

---

OCT 22, 2025

**[Perrigo to Release Third Quarter 2025 Financial Results on November 5](#)**

## [Perrigo to Release Third Quarter 2025 Financial Results on November 6, 2025](#)

---

AUG 20, 2025

## [Perrigo to Attend Barclays 18th Annual Global Consumer Staples Conference](#)

---

AUG 6, 2025

## [Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations](#)

---

JUL 30, 2025

## [Perrigo Announces Quarterly Dividend](#)

---

JUL 29, 2025

## [Perrigo to Present at the Canaccord Genuity 45th Annual Growth Conference](#)

---

JUL 23, 2025

## [Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025](#)

---

JUL 14, 2025

## [Perrigo Announces Agreement to Divest Dermacosmetics Business for up to €327 Million](#)

---

JUL 1, 2025

## [Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance](#)

---

JUN 4, 2025

**[Perrigo Announces Global Operations and Supply Chain Leadership Transition](#)**

---

MAY 23, 2025

**[Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference](#)**

---

MAY 7, 2025

**[Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations](#)**

---

APR 30, 2025

**[Perrigo Announces Quarterly Dividend](#)**

---

APR 23, 2025

**[Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025](#)**

---

FEB 28, 2025

**[Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day](#)**

---

FEB 27, 2025

**[Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations](#)**

---

FEB 26, 2025

**[Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference](#)**

---

---

FEB 19, 2025

[\*\*Perrigo Increases Quarterly Dividend by 5%\*\*](#)

---

JAN 31, 2025

[\*\*Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025\*\*](#)

---

JAN 6, 2025

[\*\*Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer\*\*](#)

---

NOV 6, 2024

[\*\*Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations\*\*](#)

---

NOV 1, 2024

[\*\*Perrigo Announces Quarterly Dividend\*\*](#)

---

OCT 23, 2024

[\*\*Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024\*\*](#)

---



SEP 26, 2024

[\*\*Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio\*\*](#)

 [Photos \(1\)](#)

---

SEP 17, 2024

**PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY**

---

SEP 12, 2024

**PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY**

---

SEP 4, 2024

**Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary**

---

AUG 27, 2024

**Perrigo to Attend the Piper Sandler Growth Frontiers Conference**

---

AUG 19, 2024

**Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer**

---

AUG 2, 2024

**Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations**

---

AUG 1, 2024

**Perrigo Announces Quarterly Dividend**

---

JUL 31, 2024

## [Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference](#)

---

JUL 19, 2024

## [Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024](#)

---

JUL 10, 2024

## [Perrigo Completes Divestment of HRA Pharma Rare Diseases Business](#)

---

MAY 28, 2024

## [Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference](#)

---

MAY 7, 2024

## [Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations](#)

---

MAY 7, 2024

## [Perrigo Announces Executive Transition for its Consumer Self-Care International \(CSCI\) Business](#)

---

MAY 1, 2024

## [Perrigo Announces Quarterly Dividend](#)

---

APR 25, 2024

## [Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million](#)

---

APR 23, 2024

[\*\*Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024\*\*](#)

---

MAR 4, 2024

[\*\*Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States\*\*](#)

 [Video](#) <sup>(1)</sup>  [Photos](#) <sup>(1)</sup>

---

FEB 29, 2024

[\*\*Perrigo to Attend UBS Global Consumer and Retail Conference\*\*](#)

---

FEB 27, 2024

[\*\*Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program\*\*](#)

---

FEB 26, 2024

[\*\*Perrigo Increases its Quarterly Dividend\*\*](#)

---

FEB 13, 2024

[\*\*Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024\*\*](#)

---

NOV 29, 2023

[\*\*Perrigo Announces Early Results of Cash Tender Offer for Notes\*\*](#)

---

NOV 16, 2023

NOV 10, 2023

## [Perrigo Announces Cash Tender Offer for Notes](#)

---

NOV 7, 2023

## [Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

---

NOV 2, 2023

## [Perrigo Announces Quarterly Dividend](#)

---

OCT 31, 2023

## [Perrigo to Attend Upcoming Consumer Investor Conferences](#)

---

OCT 24, 2023

## [Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023](#)

---

SEP 11, 2023

## [Perrigo Announces Leadership Update](#)

---

AUG 24, 2023

## [Perrigo to Attend Upcoming Consumer Investor Conferences](#)

---

AUG 8, 2023

## [Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

---

AUG 2, 2023

## [PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

---

JUL 25, 2023

## [Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference](#)

---



JUL 13, 2023

## [Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive](#)

 [Photos \(1\)](#)

---

JUN 8, 2023

## [Perrigo Appoints Patrick Lockwood-Taylor as President and CEO](#)

---

MAY 24, 2023

## [Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference](#)

---

MAY 16, 2023

## [PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE](#)

---

MAY 10, 2023

## [FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use](#)

---

MAY 9, 2023

## [Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

---

MAY 9, 2023

## [Perrigo Announces Chief Executive Officer Retirement and Succession Plan](#)

---

MAY 4, 2023

## [PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

---

APR 25, 2023

## [Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023](#)

---

MAR 28, 2023

## [Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use](#)

---



MAR 17, 2023

## [Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SoothePro™ Powdered Infant Formula](#)

 [Photos \(1\)](#)

MAR 2, 2023

## [Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference](#)

---



MAR 1, 2023

## [Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets](#)

 [Photos \(1\)](#)

FEB 28, 2023

**[Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day](#)**

---

FEB 27, 2023

**[Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations](#)**

---

FEB 21, 2023

**[Perrigo Increases its Quarterly Dividend](#)**

---

FEB 14, 2023

**[Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023](#)**

---

DEC 19, 2022

**[Perrigo to Host Virtual Investor Day on February 28, 2023](#)**

---

NOV 8, 2022

**[Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations](#)**

---

NOV 3, 2022

**[Perrigo Announces Quarterly Dividend](#)**

---



NOV 1, 2022

## **Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula**

 [Photos \(1\)](#)

---

OCT 26, 2022

## **Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use**

---

OCT 25, 2022

## **Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022**

---

SEP 12, 2022

## **PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE**

---

AUG 17, 2022

## **PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY**

---

AUG 9, 2022

## **PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS**

---

AUG 2, 2022

## **PERRIGO ANNOUNCES QUARTERLY DIVIDEND**

---

JUL 27, 2022

## [PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022](#)

---

JUL 11, 2022

## [Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill](#)

---

JUN 1, 2022

## [PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER](#)

---



MAY 26, 2022

## [PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES](#)

 [Photos \(1\)](#)

---

Show  per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [»](#)



---

<https://investor.perrigo.com/press-releases?l=100&o=0>